Single Antiplatelet Treatment With Ticagrelor or Aspirin After Transcatheter Aortic Valve Implantation
A phase 4 trial registered on ClinicalTrials.gov. The registry status is recruiting. It plans to enroll 1206 participants.
Also called NCT05283356
- Study
- In this atlas
Overview
- Design
- Interventional study; randomized; no masking; primary purpose treatment
- Phase
- Phase 4
- Enrolled
- 1,206 participants
- Sponsor
- Fundacin Biomedica Galicia Sur
- Registry
-
NCT05283356 -
2021-003927-13
-
- Started
- (actual)
- Primary completion
- (anticipated)
- Completion
- (anticipated)
- Countries
- Spain
- Registry status
- Recruiting
Technical summary
Registry record NCT05283356. Randomized; no masking; primary purpose treatment. Start 2022-01-21 (actual); primary completion 2027-06-30 (anticipated). Results not posted.
The registry's words
Labels as the registry gives them, not rewritten.
- Brief title
- Single Antiplatelet Treatment With Ticagrelor or Aspirin After Transcatheter Aortic Valve Implantation
- Acronym
- REAC-TAVI2
- Condition
- Severe Aortic Valve Stenosis
- Condition
- Aortic Valve Stenosis
- Condition
- Transcatheter Aortic Valve Implantation (TAVI)
- Intervention (Drug)
- Ticagrelor 60mg
- Lead sponsor
- Fundacin Biomedica Galicia Sur
Record details
- Record id
cardio:ct-nct05283356- Content hash
ed61f4a297598d1cf3e1cd101a080e322e192c6803c8e7ebba8f93e4c0321b24